Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus rating of “Moderate Buy” from the seventeen analysts that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $215.88.

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a report on Friday, February 16th. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 2nd.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $151.22 on Tuesday. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $218.88. The company has a market capitalization of $19.13 billion, a PE ratio of -56.43 and a beta of 0.41. The firm’s 50-day moving average price is $149.51 and its 200-day moving average price is $165.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter in the previous year, the company earned ($1.40) EPS. The company’s quarterly revenue was up 54.8% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals will post -4.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares in the last quarter. Wellington Management Group LLP lifted its position in Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after buying an additional 364,021 shares during the last quarter. Capital International Investors boosted its stake in Alnylam Pharmaceuticals by 15.8% during the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after buying an additional 488,814 shares during the period. Capital Research Global Investors increased its position in Alnylam Pharmaceuticals by 5.3% during the fourth quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company’s stock valued at $560,880,000 after acquiring an additional 146,236 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $390,438,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.